Invited Speakers
Marc Arbyn
Coordinator of the Unit of Cancer Epidemiology, Belgian Cancer Centre at the Scientific Institute of Public Health in Brussels, Belgium. Coordinator of the EU Network of Cervical Cancer Screening, editor- of the European Guidelines for Cervical Cancer Screening and associated Supplements on HPV screening, and steering group member of several international networks.
Edward Baker
Associate Professor, Dept of Obstetrics and Gynecology, University of California Davis, USA. Senior Director, Medical and Scientific Affairs, Roche Molecular Solution, Pleasanton, USA.
Jack Cuzick
Director of Wolfson Institute of Preventive Medicine in London; Head of Centre for Cancer Prevention at Queen Mary, University of London.
Previously worked at Oxford University and Columbia University, New York.
Suzanne Garland
Clinical Director of Microbiology and Infectious Diseases at The Royal Women’s Hospital and Senior Consultant in Microbiology at The Royal Children’s Hospital at the University of Melbourne, Australia. She has been a chief investigator for clinical HPV vaccine trials for both the 2-valent and 4-valent vaccines and is currently measuring vaccine effectiveness post rollout in Australia. She is a regular advisor to the WHO on sexual and reproductive health infections, cervical cancer and human papillomavirus (HPV). She is Inaugural, Past President and ongoing Board Advisor of the Asia Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) and is co-author in more than 500 peer-reviewed journals.
Chris Meijer
Professor of Pathology, Ex-Head and Director of the Department of Pathology at the VU University Medical Center, Amsterdam and Director of the Oncology Research Institute at VU University, Amsterdam, The Netherlands.
